Athersys

Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. We are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.
Company Growth (employees)
Type
Public
HQ
Cleveland, US
Founded
1995
Size (employees)
60 (est)
Athersys was founded in 1995 and is headquartered in Cleveland, US

Key People at Athersys

Gil Van Bokkelen

Gil Van Bokkelen

Chairman & CEO
William Lehmann Jr

William Lehmann Jr

President, COO
John Harrington

John Harrington

Executive Vice President and Chief Scientific Officer
Laura Campbell

Laura Campbell

Controller
Manal Morsy

Manal Morsy

Vice President, Global Regulatory Affairs

Athersys Office Locations

Athersys has offices in Cleveland and Canton
Cleveland, US (HQ)
3201 Carnegie Ave
Canton, US
250 Royall St

Athersys Metrics

Athersys Financial Metrics

Athersys's revenue was reported to be $17.3 m in 2016

Revenue (Y, 2016)

$17.3 m

Revenue growth (Y, 2015 - Y, 2016), %

45%

Net income (Y, 2016)

($15.3 m)

EBIT (Y, 2016)

($15 m)

Market capitalization (23-May-2017)

$161.4 m

Closing share price (23-May-2017)

$1.5

Cash (31-Dec-2016)

$14.8 m

EV

$146.7 m
Athersys's current market capitalization is $161.4 m.
FY, 2013FY, 2014FY, 2015Y, 2016

Revenue

$2.4 m$1.6 m$11.9 m$17.3 m

Revenue growth, %

(33%)636%45%

Operating expense total

$26.9 m$30.6 m$29.1 m$33.1 m

EBIT

($24.5 m)($29 m)($17.2 m)($15 m)

EBIT margin, %

(1003%)(1788%)(144%)(87%)

Pre tax profit

($30.7 m)($22.3 m)($16.5 m)($15.4 m)

Income tax expense

$253 k$38 k$37 k

Net Income

($30.7 m)($22.1 m)($16.4 m)($15.3 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$31.9 m$26.1 m$23 m$14.8 m

Accounts Receivable

$520 k$694 k$361 k$598 k

Current Assets

$32.9 m$27.2 m$23.8 m$16.3 m

Total Assets

$34.2 m$28.7 m$25.1 m$19.1 m

Accounts Payable

$2.2 m$2.8 m$2.7 m$4.8 m

Total Debt

$176 k$183 k$190 k

Current Liabilities

$4.4 m$4.7 m$4.8 m$6.9 m

Additional Paid-in Capital

$284.3 m$307.3 m$322.6 m$329.4 m

Retained Earnings

($264.4 m)($286.5 m)($302.9 m)($318.3 m)

Total Equity

$19.8 m$20.9 m$19.7 m$11.2 m

Debt to Equity Ratio

0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

1.7 x1.4 x1.3 x1.7 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($30.7 m)($22.1 m)($16.4 m)($15.3 m)

Depreciation and Amortization

$346 k$360 k$267 k$382 k

Accounts Receivable

($30 k)($174 k)$333 k($237 k)

Accounts Payable

($196 k)$335 k($296 k)$2.4 m

Cash From Operating Activities

($22.8 m)($25.8 m)($13.8 m)($10.9 m)

Cash From Investing Activities

($385 k)($297 k)($132 k)($1.1 m)

Cash From Financing Activities

$29.6 m$20.3 m$10.8 m$3.7 m
Y, 2016

EV/EBIT

-9.8 x

EV/CFO

-13.4 x

Financial Leverage

1.7 x

Athersys Operating Metrics

FY, 2016

Patents Issued

200

Patents (US)

21

Patent Applications

170

Athersys Market Value History

Athersys Online Presence

Athersys Company Life

You may also be interested in